Longevity.Technology vs AgingResearch.News
Choose Longevity.Technology for
Professionals, founders and investors who want the longevity industry's news (investment, biotech, supplements, clinics) in a free daily newsletter, with events, a podcast and its DLT company dataset.
Choose AgingResearch.News for
People who want the research itself: every new aging paper judged and the important ones told in plain words, each treatment's evidence on one page, and for investors, company, asset and pipeline intelligence built on that research.
Side by side
- What it is
- AgingResearch.News A reader of aging research: feeds, stories, evidence pages, news, trials and Ask
- Longevity.Technology News, a daily newsletter, a podcast, events, a clinics directory, and DLT, a dataset of companies and assets124
- Newsletter
- AgingResearch.News The Monday digest, written as an issue to read; a daily email for what you follow
- Longevity.Technology A free daily newsletter, “delivered every morning”1
- News
- AgingResearch.News The field's news, told once per event, beside stories about new papers
- Longevity.Technology Investment, Biotech, Research, AI/Tech, Supplements, Ecosystem and LT Wire3
- New papers
- AgingResearch.News Each new paper from PubMed, bioRxiv, medRxiv, arXiv and more, read as it appears and judged for what its own work shows about aging; about 1 in 20 reaches the feeds.
- Longevity.Technology Covered in its Research section3
- Company data
- AgingResearch.News Pro: company and asset profiles, the pipeline, dashboards and watchlists with alerts, built on the research. Atlas, for teams, by agreement.
- Longevity.Technology DLT: “781 longevity biotech companies” and “3,593 aging disease drug assets”, with alerts, watchlists and an AI copilot4
Where Longevity.Technology is stronger
- It covers the industry as a business: investment, deals, clinics and supplements, every morning.
- It runs events, a weekly podcast and a clinics directory; the site launched in 2019.
- Its DLT dataset pulls financial data from PitchBook, it says, and is licensed by top-10 pharma companies.
- It publishes a free longevity biotech report with market estimates.
Where AgingResearch.News is different
- It starts from the papers: each new one is read and judged for what its own work shows about aging, and the ones worth reading become stories checked against the paper.
- Each drug, gene and process has a page that shows where its evidence stands, so an asset's science can be read beside its company.
- Trials, grants and conferences are tracked with the papers.
- Ask answers questions from the papers, every claim cited.
On AgingResearch.News now
On a typical day this past week, 4,500 new papers were read and 48 stories published, from a record of 821,293 papers.
- Alzheimer imaging dataset spans healthy aging and disease
Study in people · Oct 21, 2026
- Cell identity stayed intact in aging mouse brain cells
Preprint: experiments in animals · Oct 21, 2026
- Chemical changes mark aging in animal cell recycling centers
Experiments in animals · Oct 21, 2026
- Top
The day's most significant aging research, as stories
- News
The field's news, told once per event, with the papers behind it
- Trials
Clinical trials judged for what they mean for aging
- Intelligence
Companies, assets and the pipeline, for Pro
- Rapamycin
An evidence page: species, independent labs, findings against, trials
- Conferences
The field's meetings and their abstracts
Sources
Every fact about Longevity.Technology above is from its own pages, read on the date given.
- 1. Longevity.Technology: Home, read Oct 20, 2026
- 2. Longevity.Technology: About us, read Oct 20, 2026
- 3. Longevity.Technology: News, read Oct 20, 2026
- 4. Longevity.Technology: DLT data, read Oct 20, 2026